Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MTBL0036
- Development stage
- Preclinical
- Lead developer
- Metabolys
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
MTBL0036 is an orally active small molecule mitochondrial uncoupler developed by Metabolys for the treatment of type 2 diabetes, non-alcoholic steatohepatitis (NASH), and liver fibrosis. By inducing mild mitochondrial uncoupling in the liver, MTBL0036 reduces hepatic gluconeogenesis, enhances peripheral glucose utilization, and stimulates insulin secretion. In preclinical animal models, MTBL0036 has demonstrated significant efficacy in reducing blood glucose levels, improving insulin sensitivity, and decreasing NAFLD Activity Scores (NAS) by reducing hepatic inflammation, ballooning, and fibrosis.
Beyond the preview
Go deeper on MTBL0036.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MTBL0036.